In summary, the biparatopic nanobody-based binder AH combines structural simplicity with potent functional activity, leveraging the advantages of nanobody engineering and biparatopic targeting to address key resistance mechanisms in HER2-positive cancers. The gene discussed is ERBB2; the disease is cancer.